99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.

UNLABELLED In vitro studies have demonstrated that (99m)Tc-methoxyisobutylisonitrile ((99m)Tc-MIBI) is a transport substrate of multidrug resistance (MDR)-related proteins. The aim of this clinical study was to evaluate whether (99m)Tc-MIBI scintigraphy was a functional imaging tool for in vivo detection of multidrug resistance-associated protein (MRP) expression in osteosarcoma and to investigate the role of MRP and (99m)Tc-MIBI imaging to predict the clinical outcome. We also examined whether the scintigraphic parameters would help to distinguish the functional capacity of P-glycoprotein (Pgp) and MRP. METHODS Twenty-four patients with a diagnosis of osteosarcoma were studied before neoadjuvant chemotherapy. Tumor-to-background ratios of both early (10 min) and delayed (1 h) images and the percentage washout rate (WR%) of (99m)Tc-MIBI were calculated. Immunohistochemical analysis of MRP and Pgp was performed on biopsy specimens, and the response to preoperative chemotherapy was assessed by histopathologic examination. RESULTS Fifteen of 24 osteosarcoma samples in our series (62.5%) showed significant expression of MRP. The level of MRP expression was significantly correlated with the WR% of (99m)Tc-MIBI (r = 0.58, P = 0.003), and the WR% of (99m)Tc-MIBI was significantly faster in patients with high MRP expression than in those with a low MRP score (P = 0.007). The clearance rate of (99m)Tc-MIBI was significantly slower in tumor samples with negative or low expression of both Pgp and MRP (16% +/- 6.2%) when compared with osteosarcomas with high expression of both proteins (31.7% +/- 8.7%) (P = 0.001). There was not a significant difference between the WR% of (99m)Tc-MIBI in tumors with coexpression of both proteins and in tumors with high expression of either Pgp or MRP. Both the rate of MRP expression and the WR% of (99m)Tc-MIBI were significantly correlated with response rate. CONCLUSION Our results suggest that the WR% of (99m)Tc-MIBI is correlated with MRP expression. Both the WR% of (99m)Tc-MIBI and MRP expression are correlated with therapy response. (99m)Tc-MIBI can be used as a general probe for functional imaging of both Pgp and MRP; however, it is not capable of differentiating the functional status of either MDR-related glycoprotein.

[1]  G. Schuurhuis,et al.  Transport proteins in drug resistance: detection and prognostic significance in acute myeloid leukaemia , 1997, Journal of internal medicine. Supplement.

[2]  P. D. Lee,et al.  MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Harris,et al.  Amplification and increased expression of alpha class glutathione S-transferase-encoding genes associated with resistance to nitrogen mustards. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[4]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[5]  J. Kouyoumdjian,et al.  Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  D. Mangham,et al.  Role of glutathione in cisplatin resistance in osteosarcoma cell lines , 1998, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[7]  Y. Oda,et al.  Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone , 2005, Journal of Cancer Research and Clinical Oncology.

[8]  S. Ho,et al.  Technetium‐99m‐sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P‐glycoprotein expression, multidrug resistance‐related protein expression and other prognosis factors , 2001, British journal of haematology.

[9]  S. Aggarwal,et al.  A possible role for multidrug resistance-associated protein in the secretion of basic fibroblast growth factor by osteogenic sarcoma cell line (MG-63). , 1998, International Journal of Oncology.

[10]  D. Maurici,et al.  Analysis of P-glycoprotein expression in osteosarcoma. , 1995, European journal of cancer.

[11]  T. Ishida,et al.  Overexpression of resistance‐related proteins (metallothioneins, glutathione‐S‐transferase π, heat shock protein 27, and lung resistance‐related protein) in osteosarcoma , 1997, Cancer.

[12]  I. Yamamoto,et al.  Expression of Multidrug Resistance Protein and Messenger RNA Correlate with 99mTc-MIBI Imaging in Patients with Lung Cancer , 2001 .

[13]  E. van den Berg,et al.  Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Moretti,et al.  The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response , 2001, European Journal of Nuclear Medicine.

[15]  P. Picci,et al.  P‐glycoprotein expression in osteosarcoma: A basis for risk‐adapted adjuvant chemotherapy , 1999, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[16]  D. Hipfner,et al.  Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. , 1994, Cancer research.

[17]  S. Emri,et al.  Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  F. Baas,et al.  The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Harimaya,et al.  Establishment of new multidrug-resistant human osteosarcoma cell lines. , 2000, Oncology reports.

[20]  R. Kramer,et al.  Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. , 1993, Cancer research.

[21]  H. Burger,et al.  Multidrug resistance-associated protein (MRP) in haematological malignancies. , 1996, Leukemia & lymphoma.

[22]  B. Bodey,et al.  Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression. , 1995, Anticancer research.

[23]  P. Picci,et al.  Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. , 1995, The New England journal of medicine.

[24]  R. Scheper,et al.  Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. , 1995, British Journal of Cancer.

[25]  V. Ling Multidrug resistance: molecular mechanisms and clinical relevance , 1997, Cancer Chemotherapy and Pharmacology.

[26]  K. Trieb,et al.  Proteins expressed in osteosarcoma and serum levels as prognostic factors. , 2001, The international journal of biochemistry & cell biology.

[27]  E. de Vries,et al.  Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. , 1998, European journal of biochemistry.

[28]  T. Grogan,et al.  P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. , 1997, Journal of the National Cancer Institute.

[29]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[30]  R. Schneider-Stock,et al.  Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas , 2005, Journal of Cancer Research and Clinical Oncology.

[31]  E. Franssen,et al.  Visualization of multidrug resistance in vivo , 1999, European Journal of Nuclear Medicine.